These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25225430)

  • 1. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.
    Fontanella C; Lederer B; Nekljudova V; Untch M; von Minckwitz G; Loibl S
    J Clin Oncol; 2014 Oct; 32(30):3458-9. PubMed ID: 25225430
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to C. Fontanella et al.
    Azim HA; de Azambuja E; Agbor-Tarh D; Bradbury I
    J Clin Oncol; 2014 Oct; 32(30):3459. PubMed ID: 25225439
    [No Abstract]   [Full Text] [Related]  

  • 3. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
    Azim HA; Agbor-Tarh D; Bradbury I; Dinh P; Baselga J; Di Cosimo S; Greger JG; Smith I; Jackisch C; Kim SB; Aktas B; Huang CS; Vuylsteke P; Hsieh RK; Dreosti L; Eidtmann H; Piccart M; de Azambuja E
    J Clin Oncol; 2013 Dec; 31(36):4504-11. PubMed ID: 24248687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
    Pikó B
    Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 7. Atypical cutaneous vasculitis under lapatinib.
    Peuvrel L; Quereux G; Brocard A; Saint-Jean M; Freour E; Josselin N; Audouin AF; El Kouri C; Dreno B
    Eur J Dermatol; 2013; 23(4):540-1. PubMed ID: 23965414
    [No Abstract]   [Full Text] [Related]  

  • 8. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib-induced hepatitis: a case report.
    Peroukides S; Makatsoris T; Koutras A; Tsamandas A; Onyenadum A; Labropoulou-Karatza C; Kalofonos H
    World J Gastroenterol; 2011 May; 17(18):2349-52. PubMed ID: 21633602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
    Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
    Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
    [No Abstract]   [Full Text] [Related]  

  • 14. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
    Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
    Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
    Schaid DJ; Spraggs CF; McDonnell SK; Parham LR; Cox CJ; Ejlertsen B; Finkelstein DM; Rappold E; Curran J; Cardon LR; Goss PE
    J Clin Oncol; 2014 Aug; 32(22):2296-303. PubMed ID: 24687830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
    Lin NU; Kasparian E; Morganstern DE; Beard C
    J Clin Oncol; 2009 Dec; 27(34):e218-9. PubMed ID: 19786662
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention and management of major side effects of targeted agents in breast cancer.
    Metzger Filho O; Saini KS; Azim HA; Awada A;
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e79-85. PubMed ID: 20817545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib in metastatic breast cancer.
    Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
    Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.